泰凌醫藥(01011.HK)就獲授產品商業化許可協議進入後期磋商階段
泰凌醫藥(01011.HK)公布,與一間美國註冊成立的臨床階段生物製藥公司就簽訂許可協議進入後期磋商階段,據此該公司將向公司全資附屬公司授予許可,將若干單克隆抗體產品商業化,雙方正在敲定許可協議的條款。
公司亦與一家中國公司就訂立出售協議進入後期磋商階段,據此公司全資附屬公司將有條件同意出售,及買方有條件同意購買有關附屬公司若干有形資產,雙方正在敲定出售協議的條款。
於4月29日,公司與湖北省某城市市政府及一家在中國註冊成立的公司簽訂框架協議,市政府擬投資於公司多項研發項目,特別是公司擬與該市政府在高新區成立一家合資公司作為其新總部,而該公司為專門研發、生產及銷售及服務的綜合生物科技製藥公司,將會投資於全球生物新藥;若干藥品許可權等;。
市政府擬在高新區提供一幅土地,用於設立供合資公司使用的廠房及設施;市政府亦擬提供約2億元人民幣的資金,用於設立合資公司使用的廠房及設施;及市政府或其指定平台將向合資公司投資約3億元人民幣,以持有合資公司不超過15%的股權,退出期限為三年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.